Possible side effects of Mirikizumab

Mirikizumab is a monoclonal antibody that specifically targets interleukin-23 (IL-23). It is mainly used to treat moderately to severely active ulcerative colitis as a second-line treatment. Its function is to reduce the inflammatory response by inhibiting the activity of IL-23, thereby improving the clinical manifestations of patients. Although militizumab shows good efficacy, it may also be accompanied by some adverse reactions during use.

According to the results of clinical studies, the most common adverse reactions caused by militizumab include upper respiratory tract infection, headache, rash, and injection site reactions. Upper respiratory tract infections often manifest as nose and throat discomfort, and patients may experience symptoms such as cough and sore throat.

During the induction phase of treatment, upper respiratory tract infection and joint pain are the most common side effects. During maintenance therapy, in addition to upper respiratory tract infections, patients may experience injection site reactions, joint pain, rashes, headaches, and herpes virus infections. It is worth noting that herpes virus infection may cause skin lesions, so patients need to pay close attention to related symptoms and seek medical treatment promptly when abnormalities occur.

Milizumab may also cause some serious side effects, such as allergic reactions, infections, and tuberculosis. Of particular caution, militizumab should never be used in patients with active serious infections such as tuberculosis. This is because the drug may suppress the normal function of the immune system, thereby increasing the risk of infection. Therefore, before starting treatment, doctors should conduct a thorough evaluation of the patient's infection history to ensure that they are suitable for such drugs.

In addition, relevant issues regarding hepatotoxicity and immunization need to be addressed. The use of militizumab may have a certain impact on liver function, so liver function indicators should be monitored regularly during treatment. In addition, patients should consult their doctor in advance when receiving immunizations to determine whether certain types of vaccines are suitable to avoid potential immune reactions.

Reference materials:https://www.drugs.com/history/omvoh.html